GAGE Capital

Gage is a precision medicine company focused on developing next-generation therapies for central nervous system (CNS) disorders by targeting the GABAergic system. The company utilizes a proprietary platform to design highly selective modulators of GABA-A receptor subtypes, aiming to achieve therapeutic efficacy while minimizing the side effects typically associated with non-selective GABAergic drugs like benzodiazepines. Their pipeline includes programs for epilepsy, essential tremor, and various neuropsychiatric conditions. By combining deep expertise in receptor pharmacology with advanced drug discovery tools, Gage seeks to provide transformative treatments for patients with significant unmet needs in neurology and psychiatry.